Debiopharm
Angela Zubel is an experienced professional in the field of oncology and clinical development, currently serving as the Chief Development Officer at Debiopharm International SA since February 2019. Prior to this role, Angela held key positions at Sandoz, including Global Head Clinical Development Biopharmaceuticals a.i. and Clinical Development Unit Head for Oncology from February 2016 to February 2019. Angela's expertise also includes serving as Clinical Program Leader for Oncology at Novartis Institutes for BioMedical Research from January 2011 to January 2016 and as Medical Leader in Oncology at the Healthcare Business of Merck from October 2004 to December 2010. Angela Zubel earned a Doctor of Medicine (MD) degree from Heidelberg University and has completed education at Jagiellonian University.
This person is not in the org chart
This person is not in any teams
Debiopharm
2 followers
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.